Featured
Filament Health (FH.NE): the natural psychedelic company flying under the radar
August 9, 2021
For the vast majority of the history of human use of psychedelics, they have been seen as something sacred, a gift from God or mother nature herself. Ayahuasca, which contains DMT, was given out by shamans in the Amazon as a tea. It was a spiritual experience that would purge you of your negative energy […]
The post Filament Health (FH.NE): the natural psychedelic company flying under the radar appeared first on Equity.Guru.
Pure Extracts (PULL) Confirms New Uptrend as Edibles Ship to BC
August 9, 2021
Pure Extracts (PULL) is a company that uses CO2 extraction technology to derive full spectrum oil from cannabis biomass. Their purest quality and purity makes them an emerging leader in the extraction space. What the heck does this all mean? Bear with me. Pure Extracts business model focuses on three things: extraction, formulation, and […]
The post Pure Extracts (PULL) Confirms New Uptrend as Edibles Ship to BC appeared first on Equity.Guru.
Cybin (CYBN.N) finishes its first trading day on the NYSE
August 5, 2021
The NYSE Cybin (CYBN.N) just finished its first trading day on the New York Stock Exchange (NYSE) after announcing the upcoming uplisting last month. It was a less than desirable day for the stock, but it’s really only a blip when factoring in the runup to the NYSE debut. In recent months we […]
The post Cybin (CYBN.N) finishes its first trading day on the NYSE appeared first on Equity.Guru.
Latest
Revive Therapeutics (RVV.C) provides update on psychedelic development and clinical programs
August 10, 2021
Revive Therapeutics (RVV.C) provided an update on their psychedelics development and clinical programs focused on psilocybin, which they are aiming to use to treat a number of disorders. Revive is developing a treatment for Methamphetamine Use Disorder (MUD), and is working with the Board of Regents at the University of Wisconsin System. Under the clinical […]
The post Revive Therapeutics (RVV.C) provides update on psychedelic development and clinical programs appeared first on Equity.Guru.
Core One Labs (COOL.C) subsidiary Akome initiate next step of clinical development for AKO001 and AKO003
August 9, 2021
Core One Labs’ (COOL.C) wholly-owned subsidiary Akome Biotech announced they are initiating the next step of their clinical development of their patent-pending psychedelic formulations AKO001 and AKO003. The next step involves new studies that will further enhance Akome’s knowledge supporting the use of psychedelics as strong candidates in the treatment of ischemic strokes (which AKO001 […]
The post Core One Labs (COOL.C) subsidiary Akome initiate next step of clinical development for AKO001 and AKO003 appeared first on Equity.Guru.
Filament Health (FH.NE) pulls in first Canadian psilocybin extraction and standardization patent
August 3, 2021
Filament Health (FH.NE) received the first ever psilocybin (and other associated psychoactive compounds) extraction and standardization patent for a public company by the Canadian Intellectual Property Office today, according to a press release. The patent is for the technology used in transforming psychedelic raw materials, like psilocybin-bearing mushroom, into pharma-grade extracts. This successful patent […]
The post Filament Health (FH.NE) pulls in first Canadian psilocybin extraction and standardization patent appeared first on Equity.Guru.
Mindset (MSET.C) files international patent for novel psilocybin synthesis method
August 3, 2021
Mindset Pharma (MSET.C) announced that they have filed an international patent for their novel psilocybin synthesis method. The application covers Mindset’s Synthesis Process, a process they call “ground-breaking” and “innovative”, which creates synthetic psilocybin and psilocin. They claim that their method is faster and cheaper than established synthesisation methods, on top of using easier to […]
The post Mindset (MSET.C) files international patent for novel psilocybin synthesis method appeared first on Equity.Guru.